Abstract

Evidence-based recommendations on lenalidomide (Revlimid) for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality in adults.

Is this guidance up to date?

We reviewed the evidence in September 2017. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

May 2019: A simple discount patient access scheme for lenalidomide has replaced the previous complex scheme. This does not affect the cost effectiveness of lenalidomide. Contact HTA_UKandI@celgene.com for details.

Guidance development process

How we develop NICE technology appraisal guidance